In the present study, baseline levels of CSF TNF-α, TNFR-1, and TNFR-2 were explored, and the potential to be used as a biomarker was assessed to differentiate between individuals who remain stable compared to those who experience disease progression over 10 years in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). This evidence concerns the gene TNFRSF1B and Alzheimer disease.